Startups
CAMP4 Therapeutics
Watertown, Massachusetts, United States
Watertown, Massachusetts biotechnology company developing antisense oligonucleotide therapies that increase gene expression by targeting regulatory RNA. Founded in 2016, its RAP platform combines experimental biology and computational gene regulation mapping; company disclosures describe machine learning supporting this platform. Its lead CMP-002 program targets SYNGAP1-related neurodevelopmental disorders and has received Australian and UK clearance for a Phase 1/2 study. CAMP4 paused further investment in its CMP-001 urea cycle disorder program in 2025 and is exploring partnerships. Nasdaq: CAMP.
Founded 2016
Team
 Alla SigovaSenior Vice President, Platform |
Amir NashatDirector |
Andy SchwabDirector |
Benjamin NealeScientific Advisor |
 Caleb MooreChief Business Operations Officer |
Christopher WalshScientific Advisor |
 Daniel TardiffChief Scientific Officer |
David BumcrotScientific Fellow |
 Douglas WilliamsChairman of the Board |
 Jorge CondeBoard Member (historical; current status unverified) |
 Josh Mandel-BrehmPresident & Chief Executive Officer · Director |
Karen AdelmanScientific Advisor |
 Kelly GoldChief Financial Officer |
Leonard ZonScientific Advisor · Scientific Co-Founder |
Michael MacLeanDirector |
 Michelle GatesChief People Officer |
Murray StewartDirector |
Rachel MeyersScientific Fellow |
Richard YoungDirector · Scientific Co-Founder |
 Satya KuchimanchiSenior Vice President, Technical Operations |
Steve HoltzmanDirector |
Wendy ChungScientific Advisor |
 Yuri MaricichChief Medical Officer |